Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Molecular Partners ( (MOLN) ) is now available.
On February 2, 2026, Molecular Partners announced that first-in-human imaging and dosimetry data for its DLL3-targeting Radio-DARPin candidate MP0712 were presented at the 8th Theranostics World Congress in Cape Town, covering data generated between January 29 and February 1, 2026 in five evaluable patients treated under a compassionate-use program in South Africa. The data showed specific and robust tumor uptake of MP0712 with limited accumulation in healthy tissues, supporting its further clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers and underpinning the design of an ongoing U.S. Phase 1/2a trial using the therapeutic isotope 212Pb. Management characterized the findings as validating the company’s Radio-DARPin platform for precise alpha-emitter delivery, reinforcing its strategic ambition to become a leader in alpha-targeted therapies and potentially broadening its clinical pipeline and positioning in the competitive radiopharmaceutical oncology market, with initial Phase 1 safety and activity data expected later in 2026.
The most recent analyst rating on (MOLN) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.
Spark’s Take on MOLN Stock
According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.
The score is primarily weighed down by weak financial performance (near-zero TTM revenue, ongoing losses, and significant negative free cash flow) despite low leverage. Technicals are slightly negative in the near term with muted momentum, and valuation provides limited support because the company is loss-making and no dividend yield data is available.
To see Spark’s full report on MOLN stock, click here.
More about Molecular Partners
Molecular Partners AG is a clinical-stage biotechnology company specializing in DARPin (Designed Ankyrin Repeat Protein) therapeutics, a novel class of custom-built protein drugs engineered for high affinity, specificity and flexible architecture. The company focuses on oncology, developing targeted radiopharmaceuticals (Radio-DARPins) and next-generation immune cell engagers for cancers such as small cell lung cancer and neuroendocrine tumors, with proprietary and partnered programs in preclinical and clinical stages across Europe and the United States.
Average Trading Volume: 7,177
Technical Sentiment Signal: Sell
Current Market Cap: $171.4M
Learn more about MOLN stock on TipRanks’ Stock Analysis page.